The following exposure cohorts were compared:

<ul>
<li>new users of <strong>canagliflozin</strong></li>
<li>new users of <strong>empagliflozin</strong></li>
<li>new users of <strong>dapagliflozin</strong></li>
<li>new users of empagliflozin or dapagliflozin (<strong>other SGLT2i</strong>)</li>
<li>new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA (<strong>select non-SGLT2i</strong>)</li>
<li>new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, Sulfonylureas, insulin, or other select AHA (<strong>all non-SGLT2i</strong>)</li>
</ul>

These specific ingredients are included in the drug classes mentioned above:
<ul>
<li>DPP-4 inhibitors: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin</li>
<li>GLP-1 agonists: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide</li>
<li>TZDs: pioglitazone, rosiglitazone, troglitazone</li>
<li>Sulfonylureas: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide</li>
<li>Other select AHAs:  acarbose, bromocriptine, miglitol, nateglinide, repaglinide</li>
</ul>